Back to Search
Start Over
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma:results from a Nordic Lymphoma Group phase II trial
- Source :
- Fjordén, K, Ekberg, S, Kuric, N, Smedby, K E, Lagerlöf, I, Larsen, T S, Jørgensen, J M, de Nully Brown, P & Jerkeman, M 2022, ' Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial ', British Journal of Haematology, vol. 196, no. 2, pp. 437-440 . https://doi.org/10.1111/bjh.17792
- Publication Year :
- 2022
- Subjects :
- relapsed/refractory DLBCL
business.industry
Hematology
medicine.disease
Lymphoma
Idelalisib
Transformed Lymphoma
Clinical Trials, Phase II as Topic
Treatment Outcome
Drug Resistance, Neoplasm
Purines
Recurrence
Retreatment
Relapsed refractory
medicine
Cancer research
Humans
Lymphoma, Large B-Cell, Diffuse
Molecular Targeted Therapy
transformed lymphoma
business
Diffuse large B-cell lymphoma
Phosphoinositide-3 Kinase Inhibitors
Quinazolinones
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Fjordén, K, Ekberg, S, Kuric, N, Smedby, K E, Lagerlöf, I, Larsen, T S, Jørgensen, J M, de Nully Brown, P & Jerkeman, M 2022, ' Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial ', British Journal of Haematology, vol. 196, no. 2, pp. 437-440 . https://doi.org/10.1111/bjh.17792
- Accession number :
- edsair.doi.dedup.....b79c56ed3b826d7a46616c1e34150b46